7^th World Congress on
Immunology

Gregory Lee received his Ph. D from the California Institute of Technology and completed his postdoctoral studies at the University of California, San Diego. He became a full Professor at the University of British Columbia in 1989, and retired in 2012 with the title of Professor Emeritus. He is the co-founder of Vancouver Biotech Ltd. He has published more than 200 papers, including 30 papers in cancer research. He has been serving as an editorial board member of the Journal of Carcinogenesis and Mutagenesis, and the Journal of Cancer Science and Therapy since 2012.

Antigen receptors, including immunoglobulins and T-cell receptors

Graduated MBBS University of Singapore (1965), FRACP (1975), FRCPA (1975), PhD (1977) and DSc (1986) Monash University. Heads the Autoimmunity Laboratory, Centre for Inflammatory Diseases, Department of Medicine, Monash University Faculty of Medicine and the Diagnostic Immunology Laboratory of Australian Clinical Laboratories, Clayton, Victoria. He has held positions as Head, Department of Immunology, Monash University (1995-2005) and was Chief Examiner in Immunology for the FRCPA (1995-2000). He has published 272 peer-reviewed papers, and 21 book chapters. He is currently engaged in studies directed towards understanding the immunopathology of atherosclerosis, based upon his extensive experience in the immunopathology of autoimmune gastritis and pernicious anaemia, autoimmune hepatitis and the molecular biology of early endosomes.

Immunology

Heather Medbury is a Senior Research Fellow at the University of Sydney, and is based at Westmead Hospital. She completed her PhD in transplant immunology before transferring to Vascular Biology to work for Professor John Fletcher, the head of Surgery for the University. Heather established laboratory based research for the Department of Surgery at Westmead Hospital which, combined with the large animal work operating in the Department, become known as the Vascular Biology Research Centre. Her work has received oral presentations at national and international meetings including at the American Heart Association (2004) and International Atherosclerosis Society meetings

Our research focus is cardiovascular disease. It is not just a global problem, but likely a personal one, as it doesn't just happen in someone else's family, but often within your own. Despite current treatments, patients with cardiovascular disease have a considerable residual risk of experiencing a clinical event (such as a heart attack or stroke). A challenge now is to develop strategies to prevent these remaining cardiovascular events. Though inflammation is thought to be a key contributor to residual risk, it is not a current treatment target. For the benefit of anti-inflammatory treatments to outweigh the risks, specific approaches will be required. A potential treatment target is the monocyte, as monocyte derived cells play a key role atherosclerotic plaque development and progression. Thus the focus of our group is to redefine the role of monocytes and macrophages in atherosclerosis in order to identify targets for therapeutic manipulation that could stabilize the disease. This will potentially result in a reduction in events such as heart attack and stroke that will not only decrease the morbidity and mortality associated with the disease, but also limit the associated, health, social and economic burdens it poses.

Noah Isakov is a Professor of Immunology and Chair of The Shraga Segal Department of Microbiology and Immunology at the Faculty of Health Sciences Ben Gurion University of the Negev Beer Sheva Israel. He received his PhD from the Weizmann Institute of Science in Rehovot Israel 1981 and performed postdoctoral studies at the University of Minnesota in Minneapolis MN 1981-1983 and the Scripps Research Institute in La Jolla CA 1983-1987. He performed a Sabbatical at the National Institute of Allergy and Infectious Diseases at the NIH Bethesda MD 1993-1995 and served as an Esther Z Greenberg Honors Chair in Biomedical Research at the Oklahoma Medical Research Foundation in Oklahoma City OK 2003-2004 and President of the Israel Immunological Society 2004-2006.

The general aim of our laboratory is to decipher signal transduction mechanisms that regulate T lymphocyte activation, function and differentiation into effector cells, as well as the characterisation of proto-oncogen products that are involved in cell transformation.

Kaihong Su is currently working as an Associate Professor in the Department of Pathology and Microbiology, College of medicine at University of Nebraska. Her research focuses on basic and translational research on autoimmune diseases. The ultimate goal is to understand the disease pathogenesis and identify novel biomarkers and pathways that can be developed into diagnostic/therapeutic tools for these diseases. She has completed her B.S., Nankai University (Microbiology), P. R. China, 1990 & M.S., from Nankai University (Microbiology), P. R. China in 1993. Ph.D., from University of Alabama at Birmingham (Cell Biology), Alabama, in 1998 & Post-doctoral training (Immunology) from University of Alabama at Birmingham, Alabama from 1998-2002

Immunology autoimmune diseases autoantibodies and neutrophils Research Interest

Ahmed Hegazi (or Ahmed Gaffer Hegazi; احمد جعفر حجازى) (born May 31, 1948) is currently a Professor of Microbiology and Immunology in the department of Zoonotic Diseases, National Research Center, Egypt. Prof. Hegazi received his masters degree in 1979, and his PhD in 1981. Hegazi's research work has been focused lately on bee products and their therapeutic effects. Hegazi Organized and contributed to national and international research projects since 1977 and up till now; he has been the principal investigator on multiple research projects within the National Research Center. He has published 166 scientific papers and articles in national and international journals. He also served on the board of multiple national and international scientific journals. Dr. Hegazi is also the president of the Egyptian Environmental Society for Uses and Production of Bee Products, secretary of the Egyptian Society of Apitherapy, secretary general of the African Federation of Apiculture Associations, and a member of the International Apitherapy Commission (APIMONDIA). Awards First Class Decoration of Excellence, Egypt, 1995 The Senior Scientist Prize of National Research Center, Cairo, Egypt, 1996 The National Scientific Prize In Biological Sciences, Egypt, 1990 The Scientific Prize of The National Research Center, Cairo, Egypt, 1989 The Second Best Research Paper Award, International Congress of Propolis, Bones Airs, Argentina, 2000 Main Speaker Award,10th Academic Conference, PRA and NAS (Nippon Apitherapy Soc.) Japan, 2006 2 Bronze medals from The International Innovation Fair of the Middle East, Kuwait, 2007 Patents Patent No. 8901 at 22/08/2006: A novel drug from natural products with new therapeutic modalities in treatment of psoriasis Patent No. 1005 at 02/01/2006: A novel drug from natural resources for controlling Fascioliasis Patent No. 270: at 01/06/2005: A novel drug from medicinal plants with antiatherosclerotic (hypocholesterolaemic), antioxidant and cardio protective properties. Patent No. 272: at 01/06/2005: A novel drug from natural resources with antiatherosclerotic (hypocholesterolaemic), antioxidant and cardio protective properties. Scientific Activities Editor in the following International Journals: Research Journal of Allergy, 2007 International Journal of Virology, 2007 Current Research In Tuberculosis, 2007 Research Journal of Veterinary Science, 2007 Research Journal of Microbiology, 2007 International Journal of Cancer Research, 2007 Research Journal of Medicinal plants, 2007 Referee in the following International Journals: Journal of Planta Medica, 2005 Journal of Evidence Based Complementary and Alternative Medicine, 2006 International Journal of Radiation Biology, 2007

Apitherapy, Immunology

Dr. Ian Martins has been invited to join the Editors of various international journals and has been a reviewer for various journals (approx. 40). He was appointed as the Chief Editor for International Journal of Diabetes Research (2014-2017). He is a BIT Member (BIT Congress. Inc) with an H-index of 42, (ResearchGate STATs (22), Mendeley STATS (20). The total citations over the past 27 years has accumulated to 2830. ResearchGate’s analysis available on google, Tweet, Facebook, Lindekin under Ian James Martins’ name places Dr Martins’ publication stats RG score higher than 96% of the international researchers and is now a SCIENTIST (ResearchGate). Dr Martins has received certificates of recognition at various conferences/congresses in relation to anti-aging medicine. Prevention of over eating by food restriction improves the peripheral sink hepatic abeta clearance relevant to liver lipid metabolism important to improving health and global chronic diseases.

Ethnopharmacology, Pharmacology

Dr. Mohamed Jahromi is currently working at Department of Pathology, Salmaniya Medical Complex, Bahrain. His research interest is based on Molecular Biology, Genetics, Biochemistry, Immunology, Cancer Biology, PCR, Western Blot, ELISA. He has published many articles in reputed journals.

Molecular Biology, Genetics, Biochemistry, Immunology, Cancer Biology, PCR, Western Blot, ELISA

Professor Tadamitsu Kishimoto is a world-renowned immunologist who was born in 1939 Osaka, Japan. After graduating from Osaka University Medical School in 1964, he completed a one-year internship at Osaka University Hospital, followed by Ph.D. studies in medicine from 1965 to 1969. Between 1970 and 1974, he pursued post-doctoral research in the Department of Medicine at Johns Hopkins Medical School, working under Professor Kimishige Ishizaka, the discoverer of IgE. He returned to Osaka University Medical School in Professor-Tadamitsu-Kishimoto1974 as assistant professor of medicine and progressed rapidly through his academic and research career becoming professor in 1979. He has served as dean and chairman of the Department of Medicine at Osaka University and was the university’s president from 1997-2003 and a Member of the Council for Science and Technology Policy from 2004 to 2006. Currently, he is professor of Immunology at the Immunology Frontier Research Center in Osaka University.

Post-transcriptional regulation of IL-6 has been largely uncharacterized, with the exception of the RNase Regnase-1, which prevents autoimmunity by destabilizing IL-6 mRNA

Current research projects are focused in study the complex relationships between the host and the microbiota and understand the foundations of innate immunity at a stage in which ZF larva rely 100% on it. For this porpoise we use germ-free or conventionally raised wild type or transgenic fish expressing fluorescent proteins under the control of specific promoters that further-on would be analyzed through live-imaging and molecular techniques, mainly qPCR.

raised wild type or transgenic fish expressing fluorescent proteins under the control of specific promoters that further-on would be analyzed through live-imaging and molecular techniques, mainly qPCR.

Veronica trained in medicine at St Mary’s Hospital, London. She has 3 certificates of specialist training (general medicine, respiratory medicine and clinical immunology and allergy). She has been a consultant at St Helier Hospital, Carshalton, Surrey since 1996. She was a Senior Registrar at Southampton General Hospital for 3 years, a Registrar at Royal Brompton Hospital for 3 years and at Papworth and Addenbrooks Hospital Cambridge for 2 years. Her research interests are Pulmonary fibrosis, Asthma and Anaphylaxis.

Her research interests are Pulmonary fibrosis, Asthma and Anaphylaxis. , General medicine, respiratory medicine and clinical immunology and allergy

Maulin P. Shah, currently Head and Senior Manager – Industrial Waste Water Research Lab, Division of Applied and Environmental Microbiology Lab at Enviro Technology Ltd., Ankleshwar, Gujarat, India, received his Ph.D. (2002-2005) in Environmental Microbiology from Sardar Patel University, Vallabh Vidyanagar, Gujarat. He has served as an Assistant Professor at Godhra, Gujarat University in 2001. He is a Microbial Biotechnologist with diverse research interest. A group of research scholars is working under his guidance on the areas ranging from Applied Microbiology, Environmental Biotechnology, Bioremediation, and Industrial Liquid Waste Management to solid state fermentation. His work has been focused to assess the impact of industrial pollution on microbial diversity of wastewater following cultivation dependant and cultivation independent analysis. His major work involves isolation, screening, identification and Genetic Engineering of high impact of Microbes for the degradation of hazardous materials. He has more than 140 research publication in highly reputed national and international journals. He directs the Research program at Enviro Technology Ltd., Ankleshwar. He has guided more than 20 Post Graduate students in various disciplines of Life Science. He extends his expertise in various National as well as International Reputed Journal as Editor and Editorial Board Member like Open Access Book of Cloud Publication, Journal of Environment Pollution and Human Health. He was Founder Editor-in-Chief of International Journal of Environmental Bioremediation and Biodegradation (2012-2014) as well as Journal of Applied and Environmental Microbiology (2012-2014) (Science and Education Publishing, USA), Editorial Board Member of American Journal of Microbiological Research, Electronic Journal of Energy and Environment, International Journal of Environment and Sustainability. He is also serving as a reviewer in various journals of national and international repute. Recently, he has been appointed as a Reviewer in Nature Biotechnology Journal.

Environmental Microbiology, Bio-remediation, Bio-degradation, Industrial Waste Water Treatment, Applied Microbiology, Enzyme Engineering, Liquid to Solid State Fermentation, Waste Water Genomics

Gregory Lee received his Ph. D from the California Institute of Technology and completed his postdoctoral studies at the University of California, San Diego. He became a full Professor at the University of British Columbia in 1989, and retired in 2012 with the title of Professor Emeritus. He is the co-founder of Vancouver Biotech Ltd. He has published more than 200 papers, including 30 papers in cancer research. He has been serving as an editorial board member of the Journal of Carcinogenesis and Mutagenesis, and the Journal of Cancer Science and Therapy since 2012.

Antigen receptors, including immunoglobulins and T-cell receptors